Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,565.57 +615.23 (+0.93%) CMC Crypto 200
1,434.08 +9.98 (+0.70%)
Organovo Holdings, Inc. (ONVO)
After hours:
- GlobeNewswire
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). St
- Insider Monkey
Top 15 3D Printing Companies in the US
In this article, we will take a look at the top 15 3D printing companies in the US. If you want to skip our detailed analysis, you can go directly to Top 5 3D Printing Companies in the US. Recent Trends in 3D Printing According to a report by Grand View Research, the global 3D […]
- Simply Wall St.
Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Organovo Holdings ( NASDAQ:ONVO ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.60m (loss widened by...
